الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 95 |  |  |
| | | from | 95 | | |
Abstract
Genital warts are the most common sexually transmitted diseases caused by certain types of human papillomavirus (HPV). The main clinical manifestation of genital warts is benign hyperplasia of the skin and mucous membrane in the genitalia, anus and perineum. Genital warts not only affect physiological function but also cause psychological stress (Zhu et al.,2019).
There are many strategies for treatment of genital wart like ablative therapies, e.g., topical chemical cautery, cryotherapy, electrocautery, excision, bleomycin sulfate injection and laser vaporization (Sakamoto et al., 2018), and also immunotherapy that strengthen the immune system, e.g., Imiquimod, protein purified derivative, Candida antigen, autologous vaccines, human papillomavirus vaccination and measles, mumps and rubella vaccine (Gamil et al., 2010). Immunotherapy relies on enhancement of the cell‐mediated immunity to the human papillomavirus (HPV) to induce clearance of all warts. And have led to promising results in skin diseases such as molluscum contagiosum, melanoma, and warts (Riza R, et al.,2019).
Our aim of work to achieve better methods in the management of genital warts with high efficacy and safety, and comparing between intralesional injection of PPD and CA according to their efficacy and safety.
Therefore the study was conducted of total patients 80 patients with genital warts and divided randomly into two groups each group 40 patients, one of them was treated by PPD intralesional injection, and the other group was treated by CA intralesional injection, all patients was subjected to full history taking , examination, and hypersensitivity test prior the start of the treatment, both group took 2 weeks interval between each session for total 4 sessions or until clearance, the lesions were photographed before and after the treatment, and follow up occurs after 6 months of the treatment.